Lupin acquires branded product portfolio from Shionogi in Japan

With the vision of growing globally as a drug discovery-based pharmaceutical company, Shionogi is focusing its resources on its core therapeutic and marketing areas, while continuing to create innovative medicines to support future growth and to strengthen its business operations.

Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co., Ltd. has entered into a strategic asset purchase agreement with Shionogi & Co., Ltd., on August 1, 2016, to acquire 21 long-listed products from the Japanese  pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing authorization of the products to Kyowa.

With the vision of growing globally as a drug discovery-based pharmaceutical company, Shionogi is focusing its resources on its core therapeutic and marketing areas, while continuing to create innovative medicines to support future growth and to strengthen its business operations.

As a part of this growth strategy, Shionogi would transfer 21 long-listed products to Kyowa, the Japanese subsidiary of Lupin Limited. Kyowa is amongst the top 10 Generic companies in Japan and a market leader in Central Nervous System (CNS) space well known for its “AMEL” brand, in addition to other generic pharmaceutical products in its portfolio. With this acquisition, Kyowa will rank 6th amongst generic companies in Japan.

The 21 products cover therapy areas such as Central Nervous System (CNS), Oncology, Cardiovascular and Antiinfectives. These 21 products had sales of JPY 9, 400 million (USD 90 million) collectively on NHI price basis.

Commenting on the acquisition, Mr. Nilesh Gupta, Managing Director of Lupin Limited said, "This acquisition marks Lupin’s foray into the Japanese Branded market in-line with our aspirations to build and strengthen our specialty business globally. The new Branded product portfolio has a strong fit with Lupin’s Kyowa business, as it adds depth and reach to its current CNS portfolio and other therapy areas.”

Dr. Fabrice Egros, President – Asia Pacific & Japan, Lupin Limited commented, "Japan is a very important market for us. The acquisition strongly supports our future growth plans and the brands have robust synergies with Kyowa’s existing portfolio which will enable Lupin to build a wide customer base across the key therapies.”

Dr. Isao Teshirogi, President & CEO of Shionogi said: “In the Japanese domestic prescription pharmaceutical market, the core mission of drug discovery-based pharmaceutical companies, such as Shionogi, is to create highquality new drugs and to make them available to patients. Therefore, I’m very pleased that this agreement with Kyowa could make both aspects of our mission a reality, allowing us to pursue innovative drug discovery with an even more intense focus, while ensuring that our high quality long-listed drugs continue to be delivered to patients to meet their unmet needs.”

Ajanta Pharma shines after USFDA nod

In total, Ajanta has 26 Abbreviated New Drug Application (ANDA) of which it has final approvals for 12 ANDAs; tentative approvals for 1 ANDA; and 13 ANDAs are under review with US FDA.

Ajanta Pharma Ltd is currently trading at Rs. 1757.25, up by Rs. 31.65 or 1.83% from its previous closing of Rs. 1725.6 on the BSE.

Ajanta Pharma Limited announces the receipt of final approval for Omeprazole and Sodium Bicarbonate Powder for Oral Suspension from US FDA. It is a bioequivalent generic version of Zegerid1 Powder for Oral Suspension and the company will be launching the product soon in 2 strengths 20 mg / 1680 mg & 40 mg / 1680
mg Powder Sachets.

This new approval is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated New Drug Application (ANDA) of which it has final approvals for 12 ANDAs; tentative approvals for 1 ANDA; and 13 ANDAs are under review with US FDA. 

The scrip opened at Rs. 1725 and has touched a high and low of Rs. 1776.75 and Rs. 1720.1 respectively. So far 131356(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 15186.14 crore.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1745 on 26-Jul-2016 and a 52 week low of Rs. 1103 on 18-Jan-2016. Last one week high and low of the scrip stood at Rs. 1745 and Rs. 1601.7 respectively.

The promoters holding in the company stood at 73.78 % while Institutions and Non-Institutions held 12.06 % and 14.16 % respectively.

The stock is currently trading above its 50 DMA.

Lupin launches oral contraceptives and other top pharma news

Cipla has been asked by the Supreme Court to deposit Rs 175.07 crore with regard to cases pertaining to overcharging of certain drugs, the pharmaceuticals major said.

Drug firm Lupin has launched its generic oral contraceptive Norgestimate and ethinyl estradiol tablets in the American market after receiving nod from the US health regulator.

Cipla has been asked by the Supreme Court to deposit Rs 175.07 crore with regard to cases pertaining to overcharging of certain drugs, the pharmaceuticals major said. Writ petitions filed in the Bombay High Court that were pending before the Supreme Court have been re-transferred to the Bombay High Court for a final hearing, Cipla said citing an apex court order.

Hyderabad-based Aurobindo Pharmaceuticals is planning to raise funds via a share sale to fund the acquisition of Israel-based Teva Pharmaceutical’s European assets, if its bid is accepted by this month. The company is in a race with two other multinationals for the acquisition. Good profits and a near-doubling of its market value has given the company a confidence booster for the acquisition. Which could cost it as much as $1.3 billion (Rs 8,700 crore). For the promoters of Aurobindo, it might become a bit difficult to keep their characteristic low profile intact towards the end of this month if they win the race. 

Biocon Ltd., India’s biggest biotech company, reported a 17 per cent increase in first-quarter profit, helped by healthy demand for its biosimilar drugs. Consolidated net profit for the April-June period rose to Rs.147 crore from Rs.126 crore a year-earlier. The Bengaluru-based firm said the consolidated total revenue increased by 11 per cent year-on-year to Rs.952 crore for the first quarter from Rs.857 crore. “Our strong performance this quarter has been driven by an all-round growth of our business across small molecules, biologics, branded formulations and research services,” said Kiran Mazumdar-Shaw, chairperson and managing director at Biocon. The small molecules contributed Rs.357 crore and its research unit Syngene added Rs.263 crore to the total sales for the quarter. 

Drug firm Sanofi India on Friday reported a 33 per cent rise in standalone net profit at Rs 85.3 crore for the second quarter ended June 30. The company had posted a net profit of Rs 64.2 crore for the corresponding period of the previous financial year, Sanofi India said in a filing to BSE. Standalone total income from operations of the company rose to Rs 608 crore for the quarter as against Rs 550 crore for the year-ago period. It said the board of directors has declared an interim dividend of Rs 18 per equity share of Rs 10 each. 

Biocon said it plans to launch recombinant human (rh)-insulin and long-acting insulin glargine in Malaysia in the second half of this fiscal, as it received regulatory approval from the South East Asian nation.

Biocon’s contract research arm Syngene International ha's lined up $200 million (around 3:1,342 crore) capex to bolster its manufacturing capabilities over the next three years. The company plans to invest $100 million (around 3:665.27 crore) in a greenfield facility at Mangaluru, the first phase of which would be operationalised by the financial year.2018-19. Besides, it has also earmarked another $100 million to create additional infrastructure at its existing facility at Bengaluru. 

Syngene surges 1%; plans US$ 200 mn for capex

The company plans to invest $100 million (around Rs.665 crore) in a greenfield facility at Mangalore, the first phase of which would be operationalised by financial year 2018-19.

Biocon’s research arm Syngene International is currently trading 1% higher at Rs.430 on BSE. The company has lined up US$ 200 million for capital expenditure.

The company plans to invest $100 million (around Rs.665 crore) in a greenfield facility at Mangalore, the first phase of which would be operationalised by financial year 2018-19. Besides, it has also earmarked another $100 million to create additional infrastructure at its existing facility at Bangalore.

Syngene International Ltd is currently trading at Rs. 429.1, up by Rs. 3.95 or 0.93% from its previous closing of Rs. 425.15 on the BSE.

The scrip opened at Rs. 426.9 and has touched a high and low of Rs. 434.8 and Rs. 426 respectively. So far 70092(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 8503 crore.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 458 on 05-Jul-2016 and a 52 week low of Rs. 295 on 11-Aug-2015. Last one week high and low of the scrip stood at Rs. 438 and Rs. 408 respectively.

The promoters holding in the company stood at 74.55 % while Institutions and Non-Institutions held 15.71 % and 6.85 % respectively.

The stock is currently trading above its 50 DMA.

Wockhardt rallies 7%

The scrip opened at Rs. 1077.7 and has touched a high and low of Rs. 1096.25 and Rs. 1070.35 respectively.

Wockhardt stock was higher by 7% at Rs.1114.

The scrip opened at Rs. 1077.7 and has touched a high and low of Rs. 1096.25 and Rs. 1070.35 respectively. So far 57529(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 11465.3 crore.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1748.2 on 02-Dec-2015 and a 52 week low of Rs. 706.35 on 12-Feb-2016. Last one week high and low of the scrip stood at Rs. 1049 and Rs. 911.05 respectively.

The promoters holding in the company stood at 74.19 % while Institutions and Non-Institutions held 10.39 % and 15.29 % respectively.

The stock is currently trading above its 200 DMA.

Glenmark Pharma working on proprietary product rollout and other top pharma news

Sun Pharma today announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Crestor® , Rosuvastatin Calcium tablets 5 mg (base), 10 mg (base), 20 mg (base) and 40 mg (base).

Glenmark Pharmaceuticals plans to to launch a number of proprietary products over the next decade as part of Its objective to become a specialty-driven firm. The company's long term focus Is to “launch Innovative and specialty products across markets with significant share of revenues coming from specialty and Innovation segment”, Glenmark Pharmaceuticals said In Its latest Investor presentation. It will also focus on organic growth and leveraging Internal capabilities across markets. It added. In the medium term, the emphasis Is on “continuing to grow base generics business" with the US, India and Europe to be main growth drivers, Glenmark said. 

Sun Pharma today announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Crestor® , Rosuvastatin Calcium tablets 5 mg (base), 10 mg (base), 20 mg (base) and 40 mg (base).

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rosuvastatin Calcium Tablets, 5 mg (base), 10 mg (base), 20 mg (base) and 40 mg (base). Aurobindo was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification, therefore, Aurobindo is eligible for 180 days of generic drug shared exclusivity. The product is launched in the US market.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Rosuvastatin Calcium Tablets,5 mg (base), 10 mg (base), 20 mg (base), and 40 mg (base), the generic version of Crestor Tablets, 5 mg,10 mg,20 mg,and 40 mg of IPR Pharmaceuticals, Inc. (IPR).
Government has not given permission to any pharma firm to increase prices of drugs beyond permissible limits, Parliament was informed yesterday.

Johnson & Johnson posted second-quarter profit earnings that beat analysts’ estimates, aided by the growing pharmaceutical division that is home to blockbuster products such as arthritis treatment Remicade. Remicade accounts for more than 21 per cent of drug revenue. 

To increase pharmaceutical export to the US, industries and the government should innovate and invest more on research and development of new drugs, say industry experts. Speaking at a seminar on ‘The march towards $500 billion trade’ organised by the Indo- American Chamber of Commerce, J Jayaseelan, Chairman, Indian Drug Manufacturers Association - Tamil Nadu, said though the country leads in terms of generic drug manufacturing impetus should be given to drug discovery to boost exports. India exports $5 billion worth generic drugs to the US, accounting for about 40 per cent of the drugs in the US market. India is the third largest exporter of generics but ranks 14th in terms of value. “Focus on drug discovery and capability building will increase the value of Indian drugs and improve exports,” Jayaseelan said. 

Ticel Biopark III in Coimbatore, the third such park in Tamil Nadu, is expected to be ready in 18 months, said Tamil Nadu Industry Secretary CV Sankar. Tamil Nadu was one of the first States to establish a biopark (Ticel I) for pharmaceutical and life science sectors in 2004, he said at the Indo-US Partnership Conclave – the march towards $500 billion trade – organised by the Indo-American Chamber of Commerce. 

Heightened uncertainty about the global economy following Britain’s decision to exit the European Union has dimmed the prospects of technology and select pharma stocks. Analysts are advising clients to avoid committing fresh money to most software stocks amid ambiguity about the impact of political risks of technology spending following Brexit. The Nifty IT Index has dropped 6.70% in the last month and fallen 4.72% in the last year. The Nifty Pharma index has risen 8.15% in the last month but has dived 12% in the last year. “I am not bullish on IT and pharma sectors owing to global volatility post-Brexit and cross-currency headwinds,” said Ritu Arora, director – investment, Canara HSBC Oriental Bank of Commerce Life Insurance. 

Sun Pharma gets FDA nod for generic Crestor; stock up 1%

Sun Pharmaceuticals Industries Ltd is currently trading at Rs. 790, up by Rs. 7.8 or 1% from its previous closing of Rs. 782.2 on the BSE.

Sun Pharma today announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Crestor® , Rosuvastatin Calcium tablets 5 mg (base), 10 mg (base), 20 mg (base) and 40 mg (base).

These Rosuvastatin Calcium tablets are therapeutic equivalents of IPR Pharmaceuticals, Inc.’s Crestor® tablets. As per IMS MAT May 2016, these tablets have annual sales of approximately US$ 6.8 billion in the US. These tablets are indicated for the treatment of adult patients with Hypertriglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) and adult patients with Homozygous Familial Hypercholesterolemia.

Sun Pharmaceuticals Industries Ltd is currently trading at Rs. 790, up by Rs. 7.8 or 1% from its previous closing of Rs. 782.2 on the BSE.

The scrip opened at Rs. 785 and has touched a high and low of Rs. 790.45 and Rs. 782 respectively. So far 1751117(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 188256.29 crore.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 965.15 on 20-Aug-2015 and a 52 week low of Rs. 706.4 on 24-Nov-2015. Last one week high and low of the scrip stood at Rs. 794.75 and Rs. 765 respectively.

The promoters holding in the company stood at 54.97 % while Institutions and Non-Institutions held 35.37 % and 9.65 % respectively.

The stock is currently trading above its 200 DMA.

Dr. Reddy's Lab launches Omeprazole and Sodium bicarbonate capsules in US

The Zegerid® brand and generic had U.S. sales of approximately $306.7 million MAT for the most recent twelve months ending in May 2016 according to IMS Health.

Dr. Reddy's Laboratories announced today that it has launched Omeprazole and Sodium bicarbonate capsules, 20mg/1100mg and 40mg/1100mg, a therapeutic equivalent generic version of ZEGERID (omeprazole/sodium bicarbonate) capsules in the United States market, having been approved by the U.S. Food & Drug Administration (USFDA).

The Zegerid® brand and generic had U.S. sales of approximately $306.7 million MAT for the most recent twelve months ending in May 2016 according to IMS Health.

Dr. Reddy's Omeprazole and sodium bicarbonate capsules 20 mg/1100 mg and 40 mg/1100 mg are available in bottle count size of 30.

Zegerid is a registered trademark of Santarus, Inc. a wholly owned subsidiary of Salix  Pharmaceuticals, Inc.

Dr Reddys Laboratories Ltd is currently trading at Rs. 3584.95, up by Rs. 1.9 or 0.05% from its previous closing of Rs. 3583.05 on the BSE.

The scrip opened at Rs. 3572 and has touched a high and low of Rs. 3610.8 and Rs. 3563.95 respectively. So far 113580(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 61161.93 crore.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750 on 21-Jan-2016. Last one week high and low of the scrip stood at Rs. 3633 and Rs. 3554.4 respectively.

The promoters holding in the company stood at 25.58 % while Institutions and Non-Institutions held 42.02 % and 32.4 % respectively.

The stock is currently trading above its 200 DMA.

Sun Pharma, SPARC sign licencing pact for Levetiractam ER and other top pharma news

Torrent Pharmaceuticals and Temasek-backed Intas are the latest to join the race, to acquire a band of products in Europe put on the block by Teva, the world’s largest generic drug maker. The deal, said to be valued up to $1.5 billion, has seen the Hyderabad-based Aurobindo Pharma emerge as one of the front runners in the initial rounds. The drug maker is currently working on ways to mop up finances for the deal, should it make the cut, three people familiar with the developments.

Sun Pharma Advanced Research Company Ltd (SPARC) and Sun Pharma announced a licensing arrangement for SPARC's ELEPSIA XR (Levetiracetam ER Tablets). As per arrangement, SPARC will license ELEPSIA XR (Levetiracetam Extended Release tablets) to a wholly-owned subsidiary of Sun Pharma for the US market.

Torrent Pharmaceuticals and Temasek-backed Intas are the latest to join the race, to acquire a band of products in Europe put on the block by Teva, the world’s largest generic drug maker. The deal, said to be valued up to $1.5 billion, has seen the Hyderabad-based Aurobindo Pharma emerge as one of the front runners in the initial rounds. The drug maker is currently working on ways to mop up finances for the deal, should it make the cut, three people familiar with the developments. (ET)

Dr Reddy's Laboratories expects complex generics, proprietary products, including creation of branded generics platform in the US, to be the main drivers of its growth going forward. (FC)

Glenmark Pharmaceuticals Ltd has informed BSE that subsequent to the rating received by the leading credit agencies in the world i.e. S&P and Fitch, Glenmark Pharmaceuticals limited has decided to tap into the International Bond market and is planning to raise around USD 200 mn by issuing USD denominated non-convertible unsecured bonds.

JB Chemicals & Pharmaceuticals Ltd has announced that this has reference to disclosures earlier made in relation to Order dated 8-1-2016 passed by National Green Tribunal (NGT) which, inter alia, directed the closure of industrial activities at the Company’s built drugs plant at Panoli, Gujarat. We also refer to disclosure made on May 19, 2016 informing the Exchange that NGT by Judgement and Order dated 17-5-2016 did not allow the Company’s Application for review of the Order passed on 8-1-2016 (Collectively the Orders).

US brokerage firm Jefferies said India's pharma sector may report strong revenue growth for the June quarter. It expects revenue growth of 17 per cent, led by exclusivity launches. (FC)

A second laboratory on the premises of Avon Lifesciences Ltd, from where nearly 20 tonnes of Ephedrine was seized recently, has attracted the attention of the Thane police. Investigators had alleged that the firm was diverting Ephedrine, a controlled substance used to make medicines, to drug cartels to cook the make party drug Meth. An officer linked to the probe said, “The company has one laboratory for production purposes. While conducting searches at the premises, we found a second laboratory, which appears to have been set up some time ago. When we asked why the second laboratory was needed, we did not get a convincing answer.” (IE)

Dishman Pharma’s Swiss and Ahmedabad unit gets EIR from USFDA; stock jumps 6%

Additionally, the company’s site at Naroda had also successfully completed USFDA Inspection and received the Establishment Inspection Report (EIR) for the same.

Dishman Pharmaceuticals and Chemicals informed BSE that the company's wholly owned subsidiary, namely Carbogen Amcis AG., Switzerland, had successfully completed US FDA Inspection for its two sites located at Aarau and Neuland without any adverse observations and received the Establishment Inspection Report (EIR)for the same. Thus, now the company has the above two sites in addition to Bubendorf in Switzerland, which are approved by the USFDA.

Additionally, the company’s site at Naroda had also successfully completed USFDA Inspection and received the Establishment Inspection Report (EIR) for the same.

Dishman Pharmaceuticals and Chemicals Ltd is currently trading at Rs. 140.2, up by Rs. 6.9 or 5.18% from its previous closing of Rs. 133.3 on the BSE.

The scrip opened at Rs. 132.05 and has touched a high and low of Rs. 143.4 and Rs. 131.85 respectively. So far 781511(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 2151.39 crore.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 209.85 on 04-Nov-2015 and a 52 week low of Rs. 79.78 on 20-Jul-2015. Last one week high and low of the scrip stood at Rs. 149 and Rs. 133 respectively.

The promoters holding in the company stood at 61.4 % while Institutions and Non-Institutions held 25.21 % and 13.39 % respectively.

The stock is currently trading below its 200 DMA.

Granules India unit in pact with Uspharma to acquire 12.5% stake

The company announced that its wholly owned subsidiary Granules Pharmaceuticals has entered into an agreement with USpharma to acquire 12.5% of its stake.

 

 Granules India Ltd., today announced that its wholly owned subsidiary Granules Pharmaceuticals, Inc.,(GPI} has entered into an agreement with USpharma, based in the USA, to acquire 12.5% of its stake. This investment will enable Granules to participate in product selection and have right of first refusal to market the select products which are under development by USpharma.

USpharma is a development-stage pharmaceutical company specializing in research, deve lopment and manufacture of high entry-barrier generic pharmaceuticals, including controlled-release, controlled­ substance and patent-challenge products. USpharma in collaboration with manufacturing partners had submitted five ANDAs with Paragraph IV certifications, out of which four ANDAs have already been out licensed to Granules exclusively.

USpharma has formulation development and manufacturing facilities in Philadelphia, Pennsylvania, USA, Mumbai,India and cGMP analytical laboratory in Kansas City, Missouri,USA

"The agreement with USpharma complements our internal product development  program, and expands our product portfolio by leveraging external product development capabilities. The successful development of limited competition products by USpharma provides further long-term growth for the Company. We are impressed with US Pharma's product development capabilities with niche pipeline, and firmly believe that these products represent a substantial commercial opportunity," said Mr. Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India Ltd.

Stock price:
Granules India Ltd is currently trading at Rs. 150.55, up by Rs. 5.2 or 3.58% from its previous closing of Rs. 145.35 on the BSE.

The scrip opened at Rs. 147 and has touched a high and low of Rs. 151.15 and Rs. 145.1 respectively. So far 203637(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 3153.98 crore.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 164.45 on 01-Dec-2015 and a 52 week low of Rs. 84.1 on 14-Jul-2015. Last one week high and low of the scrip stood at Rs. 149.1 and Rs. 141.2 respectively.

The promoters holding in the company stood at 51.08 % while Institutions and Non-Institutions held 8.11 % and 40.81 % respectively.

Dr Reddy’s Laboratories slips 1%; recalls over 9,000 bottles anti-organ rejection drug in US

The reason for recall is “failed impurities/degradation: out of specification result for impurity secorapamycin,” says report.

Shares of Dr Reddy’s Laboratories was lower by 1% to Rs.3574. The company recalled 9,330 bottles of Sirolimus tablets, used for prevention of organ rejection after kidney transplant, in the US due to presence of impurities, says report.

The reason for recall is “failed impurities/degradation: out of specification result for impurity secorapamycin,” says report.

The scrip opened at Rs. 3587 and has touched a high and low of Rs. 3587 and Rs. 3562.2 respectively. So far 19256(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 61584.4 crore.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750 on 21-Jan-2016. Last one week high and low of the scrip stood at Rs. 3633 and Rs. 3475.4 respectively.

The promoters holding in the company stood at 25.58 % while Institutions and Non-Institutions held 42.02 % and 32.4 % respectively.

The stock is currently trading above its 200 DMA.

Sun Pharma's leadership update for India, North America and Emerging Markets

Sun Pharma has announced that effective August 2016, Abhay Gandhi will take over as CEO, North America Business.

Sun Pharma has announced that effective August 2016, Abhay Gandhi will take over as CEO, North America Business.

Kal Sundaram will assume the position of CEO-India business and emerging markets.

Sun Pharmaceuticals Industries Ltd is currently trading at Rs. 790.9, up by Rs. 7.15 or 0.91% from its previous closing of Rs. 783.75 on the BSE.

The scrip opened at Rs. 789 and has touched a high and low of Rs. 794.75 and Rs. 775.55 respectively. So far 1252947(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 188629.34 crore.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 965.15 on 20-Aug-2015 and a 52 week low of Rs. 706.4 on 24-Nov-2015. Last one week high and low of the scrip stood at Rs. 793.25 and Rs. 774.8 respectively.

The promoters holding in the company stood at 54.97 % while Institutions and Non-Institutions held 35.37 % and 9.65 % respectively.

The stock is currently trading above its 200 DMA.

Suven Life gets patent and other top pharma news

Kalyanasundaram Subramanian, or Kal Sundaram, an old hand at Sun Pharmaceutical Industries, is coming back home. He will be leading the India and sub-continent business starting January 2017.

Pharmaceutical company Suven Life Sciences has been granted a patent each by India and South Africa for a drug used in treatment of neuro-degenerative diseases.

Kalyanasundaram Subramanian, or Kal Sundaram, an old hand at Sun Pharmaceutical Industries, is coming back home. He will be leading the India and sub-continent business starting January 2017. Post the acquisition of Ranbaxy, Sun has taken the top rank in India, with a market share of 8.7%. The decision to bring back Sundaram from Taro Pharmaceutical Industries, the money-spinning unit of Sun Pharma, signals a move that’s possibly aimed at shaping the next stage of growth for India’s largest drugmaker, analysts and industry experts said.

Scientists, including one of Indian-origin, have developed a new technology to observe the back of the eye and detect Alzheimer’s before the onset of symptoms, an advance that may help diagnose the debilitating disease early. Clinical trials are to start in this month to test the technology in humans, researchers said. The research builds upon previous work in cells by detecting changes in the retina of mice predisposed to develop Alzheimer’s.

The Medicines Patent Pool (MPP), a United Nations- backed public health organisation working to increase access to HIV viral he patitis- C and tuberculosis treatments in low and middle-income countries, has signed manufacturing licences with six Indian pharmaceutical companies to produce generic versions of antiretro virals and hepatitis-C antiviral. The companies include Aurobindo Pharma, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila, besides a Chinese company Desano, for a total of nine sub-licensing agreements.

With corporate employees spending 60-70% of their time in offices, workplace health is not an option or a benefit but a necessity. Large firms are beginning to play a larger role as far as the well-being of their workforce is concerned, but the country is not investing on preventive care, panellists said at the fifth Mint Healthcare Conclave in Mumbai on 17 June. Not doing so will mean enormous costs in terms of illness and insurance claims, they warned. 

Sun Pharma has announced that effective August 2016, Abhay Gandhi will take over as CEO, North America Business. Kal Sundaram will assume the position of CEO-India business and emerging markets.

Opto Circuits (India) Ltd has announced that wholly owned subsidiary, Eurocor Gmbh, launchesCoated Shunt Balloon Catheter, used for DIALYSIS patients which reduces re-intervention and preserves future treatment options.

Beginning this week, BD, the medical technology brand will work with diabetes management hospital professionals in Columbia Asia hospitals across India, for a period of nine months through its BD Getting Started program.

The Central TB division (CTD), Ministry of Health & Family Welfare, the North Maharashtra University (NMU) together with The International Union against Tuberculosis and Lung Disease (The Union) and United States Agency for International Development (USAID) organized a research and academia conclave in the city.

Apollo Hospitals announced that it recently signed a MoU with Stanford University for the Stanford South Asian Translational Heart Initiative (SAATHI) related to South Asians and Chronic Disease.